See more : Underground Energy Corporation (UGGYF) Income Statement Analysis – Financial Results
Complete financial analysis of Rallybio Corporation (RLYB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rallybio Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- M3-Brigade Acquisition II Corp. (MBAC-UN) Income Statement Analysis – Financial Results
- Vectura Group plc (VEC.L) Income Statement Analysis – Financial Results
- Jiangsu Zhongnan Construction Group Co., Ltd. (000961.SZ) Income Statement Analysis – Financial Results
- TTK Prestige Limited (TTKPRESTIG.NS) Income Statement Analysis – Financial Results
- Mitsubishi Kakoki Kaisha, Ltd. (6331.T) Income Statement Analysis – Financial Results
Rallybio Corporation (RLYB)
About Rallybio Corporation
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 150.00K | 167.00K | 109.00K | 62.03K | 26.34K |
| Gross Profit | -150.00K | -167.00K | -109.00K | -62.03K | -26.34K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 53.54M | 40.69M | 26.91M | 17.63M | 11.37M |
| General & Administrative | 25.39M | 27.20M | 18.74M | 7.67M | 6.28M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.39M | 27.20M | 18.74M | 7.67M | 6.28M |
| Other Expenses | 0.00 | 342.00K | 96.00K | 241.00K | 24.00K |
| Operating Expenses | 78.93M | 67.88M | 45.65M | 25.30M | 17.64M |
| Cost & Expenses | 78.93M | 67.88M | 45.65M | 25.30M | 17.64M |
| Interest Income | 6.15M | 1.96M | 54.00K | 171.00K | 197.00K |
| Interest Expense | 0.00 | 0.00 | 10.00K | 49.00K | 39.00K |
| Depreciation & Amortization | 150.00K | 167.00K | 109.00K | 62.03K | 26.34K |
| EBITDA | -72.37M | -65.41M | -45.39M | -24.83M | -17.39M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -78.93M | -67.88M | -45.65M | -25.30M | -17.64M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.37M | 2.31M | 140.00K | 363.00K | 182.00K |
| Income Before Tax | -74.56M | -65.58M | -45.51M | -24.94M | -17.46M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.04M | 908.00K | 1.50M | -15.00K | 166.00K |
| Net Income | -74.56M | -66.49M | -47.01M | -24.93M | -17.63M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.84 | -2.09 | -1.46 | -0.78 | -0.55 |
| EPS Diluted | -1.84 | -2.09 | -1.46 | -0.78 | -0.55 |
| Weighted Avg Shares Out | 40.45M | 31.82M | 32.13M | 32.13M | 32.13M |
| Weighted Avg Shares Out (Dil) | 40.45M | 31.82M | 32.13M | 32.13M | 32.13M |
4 Stocks Under $5 To Buy Now
Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations
3 Sorry Biotech Stocks to Sell in May While You Still Can
3 Biotech Stocks to Sell in May Before They Crash & Burn
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
Rallybio partners with J&J to advance therapies targeting rare fetal disease
Rallybio partners with J&J to advance therapies targeting rare fetal disease
Why Is Rallybio (RLYB) Stock Up 93% Today?
Source: https://incomestatements.info
Category: Stock Reports